4507   Shionogi & Co.,Ltd.

01/17/2022 15:00	Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comparative Clinical Trial for COVID-19 Recombinant Protein-based Vaccine
01/05/2022 11:30	Shionogi Announces Commitment to Fight COVID-19
12/27/2021 15:00	SHIONOGI Announces a Commercialization Agreement with SUSMED for a Digital Therapeutic App for Insomnia
12/27/2021 13:00	Notice Regarding the Initiation of a Global Phase 3 Clinical Trial for COVID-19 Recombinant Protein-based Vaccine, S-268019
12/20/2021 17:30	Corporate Governance Report
12/20/2021 17:00	Shionogi Announces Commitment to Address the Omicron Variant of SARS-CoV-2
12/13/2021 15:30	SHIONOGI Announces Positive Results from a Phase 2 Trial of the Regeneration Inducing Medicine S-005151 (Redasemtide) with Acute Ischemic Stroke
12/07/2021 15:00	Shionogi Announces Launch of Mutational Analysis Services for Wastewater-based Epidemiological Surveillance of the Novel Coronavirus
12/03/2021 18:00	Notice Regarding an Initiation of a Additional Dose Clinical Trial for COVID-19 Recombinant-based Vaccine
11/30/2021 13:00	Notice Regarding Reorganization of Subsidiary through Company Merger
11/25/2021 08:30	Notice Regarding the Signing of a Memorandum of Understanding with Vietnam for Infectious Disease Control, including COVID-19
11/01/2021 13:00	Consolidated Financial Results for the Second Quarter of Fiscal Year 2021 (IFRS)
11/01/2021 13:00	financial results for the second quarter of fiscal year 2021
11/01/2021 13:00	1st Half of Fiscal 2021 Financial Results
10/21/2021 11:30	Notice Regarding the Progress of Phase 2/3 Clinical Trial for New Formulation of COVID-19 Recombinant Protein-based Vaccine
09/28/2021 19:40	Shionogi R&D Day 2021
09/28/2021 19:40	Shionogi R&D Day 2021
09/28/2021 19:00	SHIONOGI announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598.
09/28/2021 11:30	Notice Regarding the Initiation of a Phase 2/3 Clinical Trial for a COVID-19 Therapeutic Agent in Japan
08/24/2021 15:00	Notice Regarding the Progress of Phase 1/2 Clinical Trial for New Formulation of COVID-19 Recombinant Protein-based Vaccine
08/02/2021 16:00	1st Quarter of Fiscal 2021 Financial Results Conference Call
08/02/2021 16:00	Supplemental material for financial results for the 1st quarter of fiscal year 2021
08/02/2021 16:00	Consolidated Financial Results for the First Quarter of Fiscal Year 2021 (IFRS)
07/28/2021 17:00	Technology Transfer for Manufacturing ofCOVID-19 Recombinant Protein-based Vaccine to Vietnam
07/26/2021 08:30	Notice Regarding the Initiation of a Phase 1 Clinical Trial for a COVID-19 Therapeutic Agent in Japan
07/21/2021 16:00	Notice of Completion of Disposal of Treasury Sharesas Restricted Stock Compensation Plan
07/16/2021 16:00	About a Phase III Clinical Study of Cancer-Specific Peptide Vaccine S-588410 in Patients with Esophageal Cancer
07/09/2021 18:30	Corporate Governance Report
06/22/2021 16:40	Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
06/01/2021 08:00	Partial Correction to Notice of Convocation of the 156th Annual General Meeting of Shareholders
05/25/2021 08:00	Items Disclosed on Internet Concerning Notice of Convocation Annual General Meeting 2021
05/25/2021 08:00	Notice of Convocation Annual General Meeting 2021
05/10/2021 15:00	FY2020 Financial Results (April 2020 March 2021)
05/10/2021 15:00	Financial results for the year ended March 31, 2021
05/10/2021 15:00	Consolidated Financial Results for Fiscal Year 2020 (IFRS)
05/06/2021 10:00	Judgment of the Complaint for the Rescission of Tax Reassessment by the Osaka Regional Taxation Bureau
04/28/2021 16:00	Position and Policy Regarding Reduction of the Investment Unit
04/28/2021 15:00	Shionogi and InveniAI initiate a research collaboration agreement aimed for AI-powered multi-target drug discovery collaboration
04/26/2021 15:00	Notice of Revisions to Dividend Forecasts (Divident Increase)
04/26/2021 13:00	Filing the Application for Marketing Approval of Th2 Chemokine TARC Kit "HISCL(R) TARC reagent"to Assist in Predicting the Exacerbation of COVID-19
04/16/2021 15:00	Agreement of Joint Sales with LumiraDx Japan for Coronavirus Antigen test agent and diagnostic instrument in Japan
03/24/2021 15:00	Notice Regarding the Status and Completion of Acquisition of Own Shares
03/23/2021 10:00	Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19
03/01/2021 16:45	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
03/01/2021 15:30	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
02/05/2021 16:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
02/01/2021 13:00	Supplemental material for financial results for the 3rd quarter of fiscal year 2020
02/01/2021 13:00	3rd Quarter of Fiscal 2020Financial Results
02/01/2021 13:00	Consolidated Financial Results for the Third Quarter of Fiscal Year 2020 (IFRS)
01/26/2021 15:00	Shionogi and BioAge conclude a license agreement aimed at treating COVID-19